Ben Enejo is a Partner at Arthur D. Little, based in the company’s Boston office, and a member of its global Healthcare & Life Sciences practice. Enejo is an experienced management consultant and industry expert, having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through commercialization. His particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.
Prior to joining Arthur D. Little, Enejo was a managing consultant at PA Consulting Group where he supported various pharmaceutical, biotech, and clinical research organizations on various transformation initiatives. He also held industry roles in pharma development before moving into management consultancy. Enejo holds a Master of Business Administration from Cranfield School of Management plus other qualifications in Molecular Medicine (MSc), Pharmacology and Physiology (BSc), and Program Management.
Areas of expertise
Clinical trial acceleration, R&D transformation incl. advanced technology application, Rare and complex disease drug launch readiness, Patient and drug safety
Group Overview
From ageing populations to chronic illnesses and the global pandemic – challenges in healthcare are mounting. But at the same time, science is rising to them. Medicine is becoming more targeted, personalized and effective. Treatments today will look primitive in comparison to those that are coming.
Arthur D. Little’s healthcare consultancy practice helps their clients adapt to change, innovate and transform to realize their potential. From boardroom to bedside, Arthur D. Little delivers lasting value to clients who are innovating at the forefront of progress in healthcare & life sciences.
Data science, wearable tech, IoT and digital connectivity – healthcare innovation is rapidly advancing to create new possibilities. Arthur D. Little’s services help clients stay ahead in the innovation race.
GROWTH ACCELERATION
Arthur D. Little supports clients to identify and realize growth opportunities outside of their core business, implementing targeted and impactful growth initiatives to create substantial growth.
COMMERCIAL READINESS
Arthur D. Little has extensive experience in helping early-stage life science companies move from R&D-focused entities to profit-making businesses with successfully commercialized products.
NEXT-GENERATION GROWTH
By identifying innovative products beyond their immediate focus, Arthur D. Little helps clients to continually target future growth and accelerate their next leap forward in performance.
INDICATION STRATEGY
Arthur D. Little assists their biopharma clients to optimize their pipeline potential, choosing the most suitable paths for their drug candidates to increase the probability of their success.
QUALITY & REGULATORY EXCELLENCE
Life sciences is one of the most regulated industries in the world. Arthur D. Little’s SUCCESS model provides a proven framework for simplification and sustainability of the clients’ quality management systems.
OPERATIONS MANAGEMENT
Arthur D. Little helps clients in healthcare and life sciences to anticipate their operational needs, establish strategic direction and unlock value by innovating to transform their operations.
DIGITAL STRATEGY
Arthur D. Little gives clients digital capabilities to optimize the functioning of their organizations, leveraging tech-led efficiencies and patient interfaces to drive better health outcomes and higher efficiency in care delivery.
COMPLEX PROCUREMENT
Arthur D. Little helps clients understand and adapt to the accelerating pace of technological change, assisting complex medtech procurements to meet tomorrow’s healthcare needs.
TECHNOLOGY/COMMERCIAL DUE DILIGENCE
Arthur D. Little works with industry and private equity clients on due-diligence assignments, offering experienced due-diligence teams with deep understanding of healthcare and life sciences.
LONG-TERM R&D STRATEGY
Arthur D. Little supports healthcare and pharmaceutical clients in the design of mid to long-term R&D strategies, analyzing future market conditions, requirements and the impact of technological innovation.
SCENARIO PLANNING
Arthur D. Little develops visionary strategies that steer the future of your organization, addressing your toughest challenges and building a portfolio of bold initiatives geared towards your success.
INNOVATION PORTFOLIO MANAGEMENT
Arthur D. Little helps clients define their innovation ambitions and manage their portfolios strategically, harnessing its energy and making it a reliable driver of growth.
Firm Overview
The world is moving faster than ever. The rules of the game are constantly shifting. People, organizations and societies are embracing change at pace and being reshaped by new technologies, deeper connectivity and the convergence of ideas and industries. And convergence isn’t just disrupting existing systems and markets – it’s creating entirely new ones, representing challenge and opportunity in equal measure.
Organisations are increasingly dealing with opposing forces which test their resolve. Performance today or innovation for tomorrow? Competition or collaboration? Investment in people or technology? Only those who can anticipate change, innovate and adapt will thrive and move ahead.
Arthur D. Little links people, technology and strategy to help clients balance these opposing forces, overcome today’s biggest challenges and seize tomorrow’s most promising opportunities. This is the difference they make.
As people, organizations and societies embrace change at pace, its leaders must anticipate, innovate and transform ever faster. We help our clients overcome today’s most pressing challenges and seize tomorrow’s most promising opportunities.
With a powerful blend of creative thinking and scientific rigor Arthur D. Little links people, technology and strategy to find original and pragmatic ways to accelerate performance, innovate through convergence and digital, and make a positive impact on the world.
